Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

NCT01042977 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

964

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Cardiovascular Disease
Inadequate Glycaemic Control

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]